A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

Trial Profile

A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Abatacept (Primary) ; Abatacept (Primary) ; Infliximab (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary) ; Tocilizumab (Primary) ; Diphenhydramine; Leflunomide; Methotrexate; Methylprednisolone; Paracetamol
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Therapeutic Use
  • Acronyms BIOBIO
  • Most Recent Events

    • 20 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
    • 20 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Sep 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top